Journal of Neurology Neurosurgery and Psychiatry

Article	Citations
Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management	266
TDP-43 proteinopathies: a new wave of neurodegenerative diseases	181
Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions	126
Pattern of cognitive deficits in severe COVID-19	109
The future of neuroprotection in stroke	98
Clinical spectrum of high-titre GAD65 antibodies	96
Advances in the management of glioblastoma	80
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy	78
Decade of progress in motor functional neurological disorder: continuing the momentum	77
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management	77
Fluid biomarkers in frontotemporal dementia: past, present and future	75
Value of systematic genetic screening of patients with amyotrophic lateral sclerosis	74
Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study	69
Cerebral microbleeds: from depiction to interpretation	68
Systematic review of psychotherapy for adults with functional neurological disorder	64
Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances	63
Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS	63
Management of functional communication, swallowing, cough and related disorders: consensus recommendations for speech and language therapy	62
LGI1 antibody encephalitis: acute treatment comparisons and outcome	62
Retinal imaging in Alzheimer’s disease	59
Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia	59
Efficacy of deep brain stimulation for treatment-resistant obsessive-compulsive disorder: systematic review and meta-analysis	58
Wilson’s disease: update on pathogenesis, biomarkers and treatments	58
Frailty, lifestyle, genetics and dementia risk	57
Functional movement disorder gender, age and phenotype study: a systematic review and individual patient meta-analysis of 4905 cases	55

Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis	52
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis	50
Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS	50
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders	49
NOTCH3 variants are more common than expected in the general population and associated with stroke and vascular dementia: an analysis of 200 000 participants	48
Anxiety and depression symptoms after COVID-19 infection: results from the COVID Symptom Study app	48
Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis	47
Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation	47
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial	47
Misdiagnosis of prolonged psychogenic non-epileptic seizures as status epilepticus: epidemiology and associated risks	46
Clinical features ofNOTCH2NLC-related neuronal intranuclear inclusion disease	45
Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients	45
Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study	45
Understanding the relationship between cognitive performance and function in daily life after traumatic brain injury	44
Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key eme	43
Neuroinflammation predicts disease progression in progressive supranuclear palsy	43
Bilateral staged magnetic resonance-guided focused ultrasound thalamotomy for the treatment of essential tremor: a case series study	42
Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits	42
Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder	41
Responsive neurostimulation of the thalamus improves seizure control in idiopathic generalised epilepsy: initial case series	40
Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon	40
Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine	39
Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion	39
Genotype-associated cerebellar profiles in ALS: focal cerebellar pathology and cerebro-cerebellar connectivity alterations	38
Defining functional brain networks underlying obsessive–compulsive disorder (OCD) using treatment-induced neuroimaging changes: a systematic review of the literature	38
Neurodegenerative disease risk among former international rugby union players	37
Neuropathology and emerging biomarkers in corticobasal syndrome	37
What is brain fog?	36
Association of obesity with disease outcome in multiple sclerosis	36
Suggestibility in functional neurological disorder: a meta-analysis	35
Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias	35
Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson’s disease: a cross-sectional study	35
Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition	35
Early lowering of blood pressure after acute intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data	35
Prognostic predictors relevant to end-of-life palliative care in Parkinson’s disease and related disorders: a systematic review	34
Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions	34
Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies	34
Real-life survey of pitfalls and successes of precision medicine in genetic epilepsies	34
Split-hand and split-limb phenomena in amyotrophic lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations	33
Intracranial arterial stenosis in Caucasian versus Chinese patients with TIA and minor stroke: two contemporaneous cohorts and a systematic review	33
Factors associated with time to independent walking recovery post-stroke	33
Impact of mobile stroke units	32
Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations	32
Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer’s disease	32
IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality	32
Systematic evaluation of genetic mutations in ALS: a population-based study	32
Multidisciplinary consensus guideline for the diagnosis and management of spontaneous intracranial hypotension	31
Rate of, and risk factors for, white matter hyperintensity growth: a systematic review and meta-analysis with implications for clinical trial design	31
Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS	31
Long-term trajectories of decline in cognition and daily functioning before and after stroke	31

Lacunar stroke: mechanisms and therapeutic implications	31
Somatic symptom disorder in patients with post-COVID-19 neurological symptoms: a preliminary report from the somatic study (Somatic Symptom Disorder Triggered by COVID-19)	31
Long-term functional decline of spontaneous intracerebral haemorrhage survivors	31
Making sense of phantom limb pain	31
Post-traumatic epilepsy in adults: a nationwide register-based study	30
Cumulative health deficits, APOE genotype, and risk for later-life mild cognitive impairment and dementia	30
Prevalence of dementia in ischaemic or mixed stroke populations: systematic review and meta-analysis	30
RFC1-related ataxia is a mimic of early multiple system atrophy	30
Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease: systematic review and meta-analysis	29
Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants	29
Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis	28
Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome	28
Quality of life in isolated dystonia: non-motor manifestations matter	28
Vaccination and multiple sclerosis in the era of the COVID-19 pandemic	28
Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension	28
Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications	28
Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes	27
Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia	27
Comorbidity of long COVID and psychiatric disorders after a hospitalisation for COVID-19: a cross-sectional study	27
Computerised patient-specific prediction of the recovery profile of upper limb capacity within stroke services: the next step	27
Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects	27
Cognitive reserve in amyotrophic lateral sclerosis (ALS): a population-based longitudinal study	27
GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance	27
Circadian rhythm of ischaemic core progression in human stroke	27
Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study	27
Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis	27
Structural and functional changes in the retina in Parkinson’s disease	26
APOE ɛ4dose associates with increased brain iron and β-amyloid via blood–brain barrier dysfunction	26
Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer’s disease	26
Functional disorders after COVID-19 vaccine fuel vaccination hesitancy	26
Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic	26
Relationship between intensity and recovery in post-stroke rehabilitation: a retrospective analysis	26
Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer’s disease	26
Longitudinal changes of spinal cord grey and white matter following spinal cord injury	25
Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis	25
Effects of 40 Hz transcranial alternating current stimulation (tACS) on cognitive functions of patients with Alzheimer’s disease: a randomised, double-blind, sham-controlled clinical trial	25
Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis	25
Endovascular treatment for large-core ischaemic stroke: a meta-analysis of randomised controlled clinical trials	25
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab	25
Ischaemic stroke in anticoagulated patients with atrial fibrillation	25
Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis	25
Sex differences for phenotype in pathologically defined dementia with Lewy bodies	25
Plasma GFAP in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study	25
Results of the COMPARE trial of Constraint-induced or Multimodality Aphasia Therapy compared with usual care in chronic post-stroke aphasia	24
Distinct latent profiles based on neurobehavioural, physical and psychosocial functioning of former National Football League (NFL) players: an NFL-LONG Study	24
Adoption of focused ultrasound thalamotomy for essential tremor: why so much fuss about FUS?	24
New classification of autoimmune neuropathies based on target antigens and involved domains of myelinated fibres	24
Comparison of efficacy of deep brain stimulation and focused ultrasound in parkinsonian tremor: a systematic review and network meta-analysis	24
The Impact of Traumatic Brain Injury on Neurocognitive Outcomes in Children: a Systematic Review and Meta-Analysis	24
Eculizumab versus rituximab in generalised myasthenia gravis	24
Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis	23
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab	23
Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective	23
Risk factors for cognitive impairment in amyotrophic lateral sclerosis: a systematic review and meta-analysis	23
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod	23
Frequency of MOG-IgG in cerebrospinal fluid versus serum	23
Prevalence, predictors and prognosis of incidental intracranial aneurysms in patients with suspected TIA and minor stroke: a population-based study and systematic review	23
Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence	23
Genotype–phenotype correlations in valosin-containing protein disease: a retrospective muticentre study	22
Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder	22
Predicting loss of independence and mortality in frontotemporal lobar degeneration syndromes	22
Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up	21
Predictors of persistent postural-perceptual dizziness (PPPD) and similar forms of chronic dizziness precipitated by peripheral vestibular disorders: a systematic review	21
Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis	21
De novo mutations in SOD1 are a cause of ALS	21
Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants	21
Multiple-region grey matter atrophy as a predictor for the development of dementia in a community: the Hisayama Study	21
Acute ischaemic stroke associated with SARS-CoV-2 infection in North America	21
Shift of multiple sclerosis onset towards older age	20
Nitrous oxide-induced myeloneuropathy: a case series	20
Prediction of dementia using diffusion tensor MRI measures: the OPTIMAL collaboration	20
Bridging versus direct endovascular therapy in basilar artery occlusion	20
Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy	20
Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis	20
Subjective cognitive complaints at age 70: associations with amyloid and mental health	20
Functional (psychogenic non-epileptic/dissociative) seizures: why and how?	19
CAIDE dementia risk score relates to severity and progression of cerebral small vessel disease in healthy midlife adults: the PREVENT-Dementia study	19
Cognitive decline and diabetes: a systematic review of the neuropathological correlates accounting for cognition at death	19
Choroid plexus enlargement in paediatric multiple sclerosis: clinical relevance and effect of sex	19
CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer’s disease	19

UNC13Ain amyotrophic lateral sclerosis: from genetic association to therapeutic target	19
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis	19
Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders	19
Prevalence and correlates of REM sleep behaviour disorder in patients with major depressive disorder: a two-phase study	18
Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function	18
Anterior limb of the internal capsule tractography: relationship with capsulotomy outcomes in obsessive-compulsive disorder	18
Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors	18
IntronicFGF14GAA repeat expansions are a common cause of ataxia syndromes with neuropathy and bilateral vestibulopathy	18
Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease	18
Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis	18
Localised increase in regional cerebral perfusion in patients with visual snow syndrome: a pseudo-continuous arterial spin labelling study	18
Multimodal prognostic features of seizure freedom in epilepsy surgery	18
Favourable arterial, tissue-level and venous collaterals correlate with early neurological improvement after successful thrombectomy treatment of acute ischaemic stroke	17
Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease	17
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study	17
Neurofilament light chain predicts future dementia risk in cerebral small vessel disease	17
Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome	17
Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study	17
Early life involvement in C9orf72 repeat expansion carriers	16
Skin biopsy and small fibre neuropathies: facts and thoughts 30 years later	16
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies	16
Long-term neuropsychiatric symptoms in spontaneous intracerebral haemorrhage survivors	16
Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours	16
Visualisation of the non-linear correlation between age and poor outcome in patients with aneurysmal subarachnoid haemorrhage	16
Diagnostic approach in adult-onset neurometabolic diseases	16
Longitudinal thalamic white and grey matter changes associated with visual hallucinations in Parkinson’s disease	16
Expanding the spectrum of VEXAS syndrome: association with acute-onset CIDP	16
Efficacy of spoken word comprehension therapy in patients with chronic aphasia: a cross-over randomised controlled trial with structural imaging	15
Early versus late start of direct oral anticoagulants after acute ischaemic stroke linked to atrial fibrillation: an observational study and individual patient data pooled analysis	15
Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study	15
Time to steroids impacts visual outcome of optic neuritis in MOGAD	15
In vivo detection of damage in multiple sclerosis cortex and cortical lesions using NODDI	15
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis	15
Surgical outcomes between temporal, extratemporal epilepsies and hypothalamic hamartoma: systematic review and meta-analysis of MRI-guided laser interstitial thermal therapy for drug-resistant epileps	15
Secondary injury and inflammation after intracerebral haemorrhage: a systematic review and meta-analysis of molecular markers in patient brain tissue	15
Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders	15
Neuromodulation for the treatment of functional neurological disorder and somatic symptom disorder: a systematic review	15
LDL cholesterol is associated with higher AD neuropathology burden independent of APOE	15
Olfactory impairment as an early marker of Parkinson’s disease in REM sleep behaviour disorder: a systematic review and meta-analysis	15
Fully automated cognitive screening tool based on assessment of speech and language	15
Sleep disturbance in movement disorders: insights, treatments and challenges	15
Clinical profile of fatal familial insomnia: phenotypic variation in 129 polymorphisms and geographical regions	15
Paraneoplastic cochleovestibulopathy: clinical presentations, oncological and serological associations	15
Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis	15
123I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease: a new quantitative analysis of autopsy confirmed cases	14
Fat-rich versus carbohydrate-rich nutrition in ALS: a randomised controlled study	14
Hypothyroidism is associated with prolonged COVID-19-induced anosmia: a case–control study	14
Interstitial laser anterior capsulotomy for obsessive–compulsive disorder: lesion size and tractography correlate with outcome	14
Anti-MOG antibody–associated disorders: differences in clinical profiles and prognosis in Japan and Germany	14
Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis	14
Mortality in patients with psychogenic non-epileptic seizures a population-based cohort study	14
Combining biomarkers for prognostic modelling of Parkinson’s disease	14
Discrepancy between disability and reported well-being after traumatic brain injury	14
Review of disease-modifying drug trials in amyotrophic lateral sclerosis	14
Possible predictors of phenoconversion in isolated REM sleep behaviour disorder: a systematic review and meta-analysis	14
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated sa	14
Disrupted reward processing in Parkinson’s disease and its relationship with dopamine state and neuropsychiatric syndromes: a systematic review and meta-analysis	14
Delirium and the risk of developing dementia: a cohort study of 12 949 patients	14
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease	14
Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study	14
Overview of cerebral cavernous malformations: comparison of treatment approaches	13
Neuro-Rehabilitation OnLine (N-ROL): description and evaluation of a group-based telerehabilitation programme for acquired brain injury	13
MOG antibody-associated encephalitis in adult: clinical phenotypes and outcomes	13
Elevated plasma p-tau181 levels unrelated to Alzheimer’s disease pathology in amyotrophic lateral sclerosis	13
Functional neurological disorder is a feminist issue	13
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum diso	13
Greater occipital nerve block modulates nociceptive signals within the trigeminocervical complex	13
Novel selection paradigms for endovascular stroke treatment in the extended time window	13
Epileptiform activity and seizures in patients with COVID-19	13
Diffusion-weighted imaging lesions and risk of recurrent stroke after intracerebral haemorrhage	13
CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab	13
Clinical practice guideline for the management of paediatric Charcot-Marie-Tooth disease	13
Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case/control cohort	13
Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up	13
Poor sleep and multiple sclerosis: associations with symptoms of multiple sclerosis and quality of life	13
Metabolic brain changes across different levels of cognitive impairment in ALS: a18F-FDG-PET study	13
The hypometabolic state: a good predictor of a better prognosis in amyotrophic lateral sclerosis	13
Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseases	13
Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions	13
Timing of physical activity across adulthood on later-life cognition: 30 years follow-up in the 1946 British birth cohort	13
MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia	12
Ischaemic stroke can follow COVID-19 vaccination but is much more common with COVID-19 infection itself	12
Effect of familial clustering in the genetic screening of 235 French ALS families	12
Temporal lobe epilepsy lateralisation and surgical outcome prediction using diffusion imaging	12
Charcot-Marie-Tooth disease type 2CC due toNEFHvariants causes a progressive, non-length-dependent, motor-predominant phenotype	12
Monoaminergic network abnormalities: a marker for multiple sclerosis-related fatigue and depression	12
Longitudinal trajectory of depression symptom severity and the influence of concussion history and physical function over a 19-year period among former National Football League (NFL) players: an NFL-L	12
Plasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer’s disease：a systematic review with meta-analysis	12
Parsonage-Turner syndrome following COVID-19 vaccination	12
Development of a sensitive trial-ready poly(GP) CSF biomarker assay forC9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis	12
Advances in neuroimaging to support translational medicine in dementia	12
Sensitivity of brain MRI and neurological examination for detection of upper motor neurone degeneration in amyotrophic lateral sclerosis	12
Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia	12
Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT	12
Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy	12